ASCO: Melanoma immunotherapy continues to show success
PUBLISHED: JUNE 02, 2014
After a long period with little progress, a number of new therapies for treating melanoma were highlighted at recent ASCO annual meetings, and this year was no exception. Hoping to build on the successful introduction of the immunotherapy drug Yervoy (ipilimumab), researchers investigated whether it would be effective in treating patients with earlier-stage disease who remained at high risk of recurrence after surgery. Yervoy was approved in 2011 for treating inoperable, late-stage melanoma.
In the phase 3 study, 951 participants whose stage 3 melanoma had been surgically treated were randomized to receive Yervoy or a placebo. After 2.7 years, Yervoy was shown to reduce the risk of recurrence by about 25 percent compared with placebo. However, participants experienced considerable side effects, including inflammation of the colon, thyroid and pituitary gland, as well as skin rash. In fact, more than half (52 percent) of participants discontinued the treatment because of side effect severity, and five treatment-related deaths occurred.
Two other drugs--nivolumab and pembrolizumab--showed success in early phase 1 trials. In a large study of 411 participants with advanced melanoma, pembrolizumab proved effective in participants who had received multiple prior therapies, including Yervoy, as well as those whose metastatic disease was newly diagnosed. Overall, 34 percent of participants experienced tumor response, with an estimated survival rate of 69 percent. Twelve percent of participants experienced treatment-related side effects, but were considered manageable. Pembrolizumab, an antibody that blocks a pathway on T-cells, previously received a breakthrough therapy designation for treating inoperable, late-stage illness, and was granted a priority review under the Food and Drug Administration's accelerated approval program in May.
In a third study, researchers investigated whether combining the antibody drug nivolumab with Yervoy would improve long-term survival for patients with advanced melanoma. Results showed that 41 percent of the 53 participants responded to the treatment, with 17 percent experiencing complete remissions. The median survival rate was about 40 months, and side effects were considered manageable and reversible.
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs.
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).